Hub : Traits :

Number of treatments/medications taken

220 significantly associated models · 44 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	109126153	110517617	2	1	7.5e-08	1.5e-07	4.4e-01	98	SORT1
2	2	26624843	28038799	1	1	2.5e-07	3.7e-06	8.5e-05	28	CGREF1
3	3	48702606	50932324	14	1	8.5e-12	2.6e-11	2.6e-01	97	MST1R
4	4	102868793	104627833	6	1	1.5e-10	9.8e-10	1.0e+00	100	CISD2
5	5	113846922	115239004	1	1	2.8e-07	5.4e-06	2.8e-03	57	CTC-428G20.3
6	7	73425238	74494207	2	1	2.7e-08	1.2e-06	1.2e-01	90	PMS2P5
7	10	21123825	22724472	1	1	5.8e-08	1.6e-07	2.7e-01	96	MLLT10
8	10	133048749	134466163	1	1	1.4e-07	8.5e-07	8.4e-02	88	PPP2R2D
9	11	100168289	101559718	1	1	1.7e-07	1.1e-06	2.4e-02	78	TMEM133
10	12	111154626	113517494	3	1	1.1e-09	1.7e-14	1.2e-06	60	SH2B3
11	14	74424938	76089054	4	1	3.7e-11	6.1e-11	3.3e-01	98	RPS6KL1
12	15	80743350	81292020	1	1	1.1e-10	1.6e-09	5.0e-01	99	FAM108C1
13	15	91181489	91686147	1	1	1.5e-07	5.0e-05	6.0e-01	98	FES
14	17	47119135	47685050	1	1	3.3e-08	3.0e-11	1.3e-06	47	ZNF652
15	17	65431947	66828158	1	1	2.2e-07	5.1e-07	6.1e-01	99	SH3GL1P3
16	20	57525478	58079512	1	1	2.2e-08	4.6e-09	5.6e-03	78	ZNF831

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
LDL Cholesterol	33.13	2	1	2.2	0.00	1.0e+00	SH2B3 SORT1
Cardiovascular Disease	15.76	11	9	20.0	0.94	2.1e-05	CGREF1 CISD2 FAM108C1 FES MLLT10 PMS2P5 SH2B3 SORT1 TMEM133 ZNF652 ZNF831
Vascular/heart problems diagnosed by doctor	15.57	12	8	17.8	-0.92	1.7e-05	CGREF1 CISD2 CTC-428G20.3 FAM108C1 FES MLLT10 PMS2P5 PPP2R2D SH2B3 TMEM133 ZNF652 ZNF831
High cholesterol (Self-reported)	15.50	3	2	4.4	0.00	1.0e+00	CGREF1 SORT1 TMEM133
Blood Eosinophil Count	14.56	5	4	8.9	0.76	1.3e-01	MST1R SH2B3 SH3GL1P3 ZNF652 ZNF831
Medication: Cholesterol lowering	14.53	5	2	4.4	0.16	7.9e-01	CGREF1 FES SORT1 TMEM133 ZNF831
Medication for cholesterol, blood pressure or diabetes	13.93	9	5	11.1	-0.96	2.8e-05	CISD2 FAM108C1 FES MST1R SH2B3 SORT1 TMEM133 ZNF652 ZNF831
High blood pressure	13.91	11	7	15.6	0.94	2.0e-05	CGREF1 CISD2 CTC-428G20.3 FAM108C1 FES MLLT10 PMS2P5 SH2B3 TMEM133 ZNF652 ZNF831
Hypertension (Self-reported)	13.67	11	7	15.6	0.94	2.2e-05	CGREF1 CISD2 CTC-428G20.3 FAM108C1 FES MLLT10 PMS2P5 SH2B3 TMEM133 ZNF652 ZNF831
Systolic Blood Pressure	12.66	12	8	17.8	0.73	7.1e-03	CGREF1 FAM108C1 FES MLLT10 PMS2P5 PPP2R2D RPS6KL1 SH2B3 SH3GL1P3 TMEM133 ZNF652 ZNF831
Medication: Blood pressure	12.52	7	7	15.6	0.98	1.6e-04	CISD2 FAM108C1 FES SH2B3 TMEM133 ZNF652 ZNF831
Diastolic blood pressure, automated reading	11.81	11	7	15.6	0.91	1.2e-04	CISD2 CTC-428G20.3 FAM108C1 FES MLLT10 MST1R PMS2P5 SH2B3 TMEM133 ZNF652 ZNF831
Taking other prescription medications	11.39	8	4	8.9	0.99	3.8e-06	CISD2 MLLT10 MST1R PMS2P5 RPS6KL1 SH2B3 SH3GL1P3 ZNF652
Number of self-reported non-cancer illnesses	11.19	8	5	11.1	0.98	1.6e-05	CGREF1 CISD2 MLLT10 PMS2P5 RPS6KL1 SH2B3 ZNF652 ZNF831
Medication: Simvastatin	11.15	3	1	2.2	0.00	1.0e+00	FES SORT1 ZNF831
Medication: Blood pressure	11.13	8	5	11.1	0.96	1.7e-04	CISD2 FAM108C1 FES RPS6KL1 SH2B3 TMEM133 ZNF652 ZNF831
Medication for cholesterol	10.26	9	3	6.7	-0.99	1.1e-06	CGREF1 CISD2 FAM108C1 FES RPS6KL1 SH2B3 SORT1 TMEM133 ZNF831
Medication: Atorvastatin	9.82	2	1	2.2	0.00	1.0e+00	CGREF1 SORT1
Systolic blood pressure, automated reading	9.80	7	5	11.1	0.90	5.2e-03	FAM108C1 FES PMS2P5 RPS6KL1 SH2B3 TMEM133 ZNF831
Cholesterol lowering medication	9.19	1	1	2.2	0.00	1.0e+00	SORT1
Angina	7.95	3	3	6.7	0.00	1.0e+00	FES SORT1 ZNF652
Hypothyroidism (self reported)	7.85	2	1	2.2	0.00	1.0e+00	RPS6KL1 SH2B3
Overall health rating	7.83	8	3	6.7	0.97	3.8e-05	CISD2 CTC-428G20.3 MLLT10 MST1R PMS2P5 PPP2R2D SH3GL1P3 ZNF652
Angina (self-reported)	7.75	3	2	4.4	0.00	1.0e+00	FES SORT1 ZNF652
Medication: Atenolol	7.57	3	2	4.4	0.00	1.0e+00	FES SH2B3 TMEM133
Medication for pain relief, constipation, heartburn	7.24	6	2	4.4	-0.99	7.6e-05	CGREF1 CISD2 FAM108C1 MLLT10 RPS6KL1 SH3GL1P3
Medication: Aspirin	6.99	3	2	4.4	0.00	1.0e+00	FES SH2B3 SORT1
Blood White Count	6.94	5	4	8.9	0.89	4.1e-02	CGREF1 FES MST1R SH2B3 ZNF652
High blood pressure (siblings)	6.89	4	0	0.0	1.00	4.3e-03	CGREF1 FES SH2B3 TMEM133
Medication: Amlodipine	6.88	3	2	4.4	0.00	1.0e+00	FAM108C1 FES TMEM133
Medication: Aspirin	6.86	2	2	4.4	0.00	1.0e+00	FES SORT1
Heart attack	6.76	5	1	2.2	0.99	1.2e-03	FES SH2B3 SORT1 ZNF652 ZNF831
Triglycerides	6.70	2	1	2.2	0.00	1.0e+00	CGREF1 SH3GL1P3
Heart attack/myocardial infarction (self-reported)	6.62	4	1	2.2	1.00	5.8e-04	FES SH2B3 SORT1 ZNF652
Leg fat percentage (right)	6.60	6	4	8.9	0.94	4.7e-03	FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Hypothyroidism/myxoedema (self-reported)	6.58	1	1	2.2	0.00	1.0e+00	SH2B3
Medication: Levothyroxine sodium	6.57	1	1	2.2	0.00	1.0e+00	SH2B3
Leg fat percentage (left)	6.54	6	4	8.9	0.95	3.8e-03	FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Leg fat mass (right)	6.50	5	5	11.1	0.98	4.2e-03	FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Leg fat mass (left)	6.49	5	5	11.1	0.98	3.8e-03	FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
High blood pressure (mother)	6.47	3	1	2.2	0.00	1.0e+00	CGREF1 FES ZNF831
Medication: Bendroflumethiazide	6.36	5	0	0.0	0.99	4.6e-04	CISD2 FAM108C1 FES SH2B3 ZNF831
Medication: Ramipril	6.29	3	0	0.0	0.00	1.0e+00	CISD2 FES TMEM133
Illnesses of siblings	6.24	3	0	0.0	0.00	1.0e+00	FES SH2B3 TMEM133
Body mass index (BMI)	6.02	5	5	11.1	0.97	7.0e-03	FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Long-standing illness, disability or infirmity	5.86	4	0	0.0	1.00	1.3e-04	CTC-428G20.3 PMS2P5 SH3GL1P3 ZNF652
Whole body fat mass	5.82	5	4	8.9	0.99	2.1e-03	FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Waist circumference	5.78	5	5	11.1	0.98	3.5e-03	FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Illnesses of father: Heart disease	5.78	3	2	4.4	0.00	1.0e+00	FES SH2B3 SORT1
BMI	5.75	8	5	11.1	0.92	1.3e-03	CISD2 CTC-428G20.3 FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3 ZNF652
Body fat percentage	5.75	6	3	6.7	0.95	3.9e-03	FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Illnesses of mother	5.66	1	1	2.2	0.00	1.0e+00	FES
Illnesses of father: High blood pressure	5.65	2	1	2.2	0.00	1.0e+00	FES SH2B3
Illnesses of father: None of the above (group 1)	5.54	2	1	2.2	0.00	1.0e+00	FES SH2B3
Arm fat mass (left)	5.49	5	5	11.1	0.98	2.5e-03	FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Arm fat mass (right)	5.47	5	5	11.1	0.99	1.9e-03	FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Qualifications: A levels/AS levels or equivalent	5.43	2	1	2.2	0.00	1.0e+00	MST1R PPP2R2D
Trunk fat mass	5.31	5	4	8.9	0.98	2.5e-03	FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Qualifications: College or University degree	5.18	3	2	4.4	0.00	1.0e+00	MLLT10 MST1R PPP2R2D
Trunk fat percentage	5.16	6	3	6.7	0.94	5.0e-03	FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Arm fat percentage (left)	5.10	6	4	8.9	0.94	5.9e-03	FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Father's age at death	5.03	4	1	2.2	-0.98	1.7e-02	FES MST1R SH2B3 SORT1
Arm fat percentage (right)	5.00	6	4	8.9	0.94	4.7e-03	FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Pain experienced in last month	4.90	5	1	2.2	-0.65	2.3e-01	FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3
Fed-up feelings	4.84	3	3	6.7	0.00	1.0e+00	MST1R RPS6KL1 SH2B3
Age at First Birth	4.80	2	1	2.2	0.00	1.0e+00	MST1R ZNF652
Weight	4.80	6	5	11.1	0.76	7.8e-02	FAM108C1 MLLT10 MST1R PMS2P5 SH2B3 SH3GL1P3
Wheeze or whistling in the chest in last year	4.80	4	1	2.2	0.96	3.7e-02	MST1R RPS6KL1 SH3GL1P3 ZNF652
Age at last live birth	4.69	2	1	2.2	0.00	1.0e+00	MST1R SH3GL1P3
Birth weight of first child	4.54	2	2	4.4	0.00	1.0e+00	FES SH2B3
Medication: Paracetamol	4.43	2	0	0.0	0.00	1.0e+00	CGREF1 MLLT10
Alcohol intake frequency.	4.42	3	3	6.7	0.00	1.0e+00	CGREF1 MST1R PMS2P5
Impedance of arm (left)	4.40	7	3	6.7	-0.60	1.6e-01	CGREF1 CISD2 FAM108C1 MLLT10 MST1R SH2B3 ZNF652
Number of operations (self-reported)	4.36	2	0	0.0	0.00	1.0e+00	MLLT10 MST1R
Age at first live birth	4.35	1	1	2.2	0.00	1.0e+00	MST1R
Medication: Lisinopril	4.29	2	0	0.0	0.00	1.0e+00	SH2B3 ZNF831
Impedance of arm (right)	4.17	8	3	6.7	-0.64	8.9e-02	CGREF1 CISD2 FAM108C1 MLLT10 MST1R PMS2P5 SH2B3 ZNF652
Impedance of whole body	4.14	7	4	8.9	-0.81	2.7e-02	CGREF1 CISD2 FAM108C1 MLLT10 MST1R PMS2P5 ZNF652
Medication: Paracetamol	4.12	2	0	0.0	0.00	1.0e+00	CGREF1 MLLT10
Hip circumference	3.99	6	4	8.9	0.74	9.0e-02	FAM108C1 MLLT10 MST1R PMS2P5 SH2B3 SH3GL1P3
Coronary Artery Disease (CAD)	3.90	2	0	0.0	0.00	1.0e+00	MST1R SH2B3
Mean time to correctly identify matches	3.90	1	1	2.2	0.00	1.0e+00	SH2B3
Fasting Glucose	3.88	1	1	2.2	0.00	1.0e+00	CGREF1
Qualifications: None of the above	3.82	2	2	4.4	0.00	1.0e+00	MST1R PPP2R2D
Intelligence (Savage-Jansen 2018)	3.77	2	1	2.2	0.00	1.0e+00	MST1R PPP2R2D
Arm predicted mass (left)	3.77	7	2	4.4	0.29	5.2e-01	CGREF1 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3 SORT1
Arm fat-free mass (left)	3.76	7	2	4.4	0.30	5.2e-01	CGREF1 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3 SORT1
Neuroticism	3.75	2	1	2.2	0.00	1.0e+00	MST1R RPS6KL1
Irritable Bowel Disease (IBD)	3.73	2	1	2.2	0.00	1.0e+00	MST1R PMS2P5
Asthma	3.66	3	1	2.2	0.00	1.0e+00	MLLT10 MST1R ZNF652
Health satisfaction	3.64	2	0	0.0	0.00	1.0e+00	MST1R SH3GL1P3
Arm predicted mass (right)	3.64	7	3	6.7	0.30	5.2e-01	CGREF1 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3 SORT1
Depressed Affect (Nagel 2018)	3.60	3	2	4.4	0.00	1.0e+00	MST1R RPS6KL1 SH2B3
Medication: Omeprazole	3.59	1	0	0.0	0.00	1.0e+00	MST1R
Ulcerative Colitis (UC)	3.58	1	1	2.2	0.00	1.0e+00	MST1R
Loneliness, isolation	3.58	3	0	0.0	0.00	1.0e+00	MST1R SH2B3 SH3GL1P3
Asthma (self-reported)	3.58	2	1	2.2	0.00	1.0e+00	MST1R ZNF652
Gout (self-reported)	3.55	2	1	2.2	0.00	1.0e+00	CGREF1 SH2B3
Leg pain on walking	3.55	1	1	2.2	0.00	1.0e+00	MST1R
Mood swings	3.52	2	2	4.4	0.00	1.0e+00	MST1R RPS6KL1
Arm fat-free mass (right)	3.51	7	2	4.4	0.27	5.5e-01	CGREF1 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3 SORT1
Basal metabolic rate	3.47	7	4	8.9	0.34	4.5e-01	CGREF1 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3 SORT1
Impedance of leg (left)	3.45	6	3	6.7	-0.43	3.9e-01	FAM108C1 FES MST1R PMS2P5 RPS6KL1 ZNF652
Impedance of leg (right)	3.37	6	3	6.7	-0.45	3.7e-01	FAM108C1 FES MST1R PMS2P5 RPS6KL1 ZNF652
Neuroticism score	3.37	2	1	2.2	0.00	1.0e+00	MST1R RPS6KL1
Blood Platelet Count	3.35	3	3	6.7	0.00	1.0e+00	CGREF1 RPS6KL1 SH2B3
Lung FEV1/FVC ratio	3.35	6	4	8.9	-0.04	9.4e-01	MLLT10 RPS6KL1 SH3GL1P3 SORT1 TMEM133 ZNF652
Past tobacco smoking	3.33	4	0	0.0	-0.99	9.2e-03	MLLT10 RPS6KL1 SH2B3 ZNF652
Breast Cancer	3.28	2	2	4.4	0.00	1.0e+00	FES MLLT10
Ever highly irritable/argumentative for 2 days	3.26	1	1	2.2	0.00	1.0e+00	MST1R
Leg predicted mass (left)	3.24	8	2	4.4	0.47	2.4e-01	CGREF1 FAM108C1 MLLT10 MST1R PMS2P5 PPP2R2D SH2B3 SH3GL1P3
Smoking Status	3.23	3	1	2.2	0.00	1.0e+00	FAM108C1 MLLT10 ZNF652
Leg fat-free mass (left)	3.23	7	2	4.4	0.57	1.9e-01	CGREF1 FAM108C1 MLLT10 MST1R PMS2P5 SH2B3 SH3GL1P3
Smoking status: Previous	3.23	2	0	0.0	0.00	1.0e+00	MLLT10 SH2B3
Alcohol intake versus 10 years previously	3.17	1	1	2.2	0.00	1.0e+00	MST1R
Whole body water mass	3.17	8	2	4.4	0.08	8.6e-01	CGREF1 FAM108C1 MLLT10 MST1R RPS6KL1 SH2B3 SH3GL1P3 SORT1
Whole body fat-free mass	3.14	7	2	4.4	-0.04	9.3e-01	CGREF1 FAM108C1 MST1R RPS6KL1 SH2B3 SH3GL1P3 SORT1
Respiratory disease	3.13	2	1	2.2	0.00	1.0e+00	MST1R ZNF652
Medication: Seretide 50 evohaler	3.13	2	0	0.0	0.00	1.0e+00	MST1R ZNF652
Ovarian Cancer	3.12	1	1	2.2	0.00	1.0e+00	MLLT10
Other serious medical condition/disability diagnosed by doctor	3.12	1	0	0.0	0.00	1.0e+00	PMS2P5
Medication: Ventolin 100micrograms inhaler	3.11	2	0	0.0	0.00	1.0e+00	MST1R ZNF652
Leg predicted mass (right)	3.06	9	2	4.4	0.24	5.3e-01	CGREF1 FAM108C1 MLLT10 MST1R PMS2P5 PPP2R2D RPS6KL1 SH2B3 SH3GL1P3
Leg fat-free mass (right)	3.05	9	2	4.4	0.25	5.2e-01	CGREF1 FAM108C1 MLLT10 MST1R PMS2P5 PPP2R2D RPS6KL1 SH2B3 SH3GL1P3
Knee pain experienced in last month	3.04	2	0	0.0	0.00	1.0e+00	CTC-428G20.3 MST1R
Diabetes (self-reported)	3.03	2	0	0.0	0.00	1.0e+00	MST1R PMS2P5
Reaction Time	3.02	1	1	2.2	0.00	1.0e+00	SH2B3
Maternal smoking around birth	3.01	2	0	0.0	0.00	1.0e+00	MLLT10 MST1R
Heart disease (siblings)	3.01	1	0	0.0	0.00	1.0e+00	FES
Allergy	2.99	1	1	2.2	0.00	1.0e+00	ZNF652
Diabetes diagnosed by doctor	2.98	1	0	0.0	0.00	1.0e+00	MST1R
Primary Biliary Cirrhosis	2.94	2	1	2.2	0.00	1.0e+00	CISD2 SH2B3
Trunk fat-free mass	2.93	6	3	6.7	-0.24	6.5e-01	CGREF1 FAM108C1 MST1R RPS6KL1 SH2B3 SORT1
Bilateral oophorectomy (both ovaries removed)	2.92	1	0	0.0	0.00	1.0e+00	MLLT10
Ulcerative Colitis	2.91	1	1	2.2	0.00	1.0e+00	MST1R
Birth weight	2.90	2	2	4.4	0.00	1.0e+00	FES SH2B3
Trunk predicted mass	2.89	6	3	6.7	-0.24	6.4e-01	CGREF1 FAM108C1 MST1R RPS6KL1 SH2B3 SORT1
Neuroticism (Nagel 2018)	2.87	1	1	2.2	0.00	1.0e+00	RPS6KL1
Medication: Metformin	2.85	1	0	0.0	0.00	1.0e+00	CISD2
Ever unenthusiastic/disinterested for a whole week	2.85	1	0	0.0	0.00	1.0e+00	RPS6KL1
Qualifications: O levels/GCSEs or equivalent	2.83	2	0	0.0	0.00	1.0e+00	MST1R PPP2R2D
HDL Cholesterol	2.82	1	1	2.2	0.00	1.0e+00	SORT1
Ever had hysterectomy (womb removed)	2.82	1	0	0.0	0.00	1.0e+00	MLLT10
Verbal and Numeric Reasoning (VNR)	2.78	1	1	2.2	0.00	1.0e+00	MST1R
Crohns Disease (2012)	2.76	1	1	2.2	0.00	1.0e+00	MST1R
Fluid intelligence score	2.76	1	1	2.2	0.00	1.0e+00	MST1R
Type 2 Diabetes (T2D) (2018)	2.75	2	0	0.0	0.00	1.0e+00	MST1R SH2B3
Medication: Allopurinol	2.71	2	0	0.0	0.00	1.0e+00	CGREF1 SH2B3
Miserableness	2.71	1	1	2.2	0.00	1.0e+00	MST1R
Schizophrenia (2014)	2.68	2	1	2.2	0.00	1.0e+00	CISD2 FES
Age when periods started (menarche)	2.67	3	1	2.2	0.00	1.0e+00	FAM108C1 MST1R PMS2P5
Guilty feelings	2.67	1	1	2.2	0.00	1.0e+00	RPS6KL1
Chronic bronchitis/emphysema (mother)	2.65	1	0	0.0	0.00	1.0e+00	MST1R
Smoking status: Current	2.63	1	0	0.0	0.00	1.0e+00	SH3GL1P3
Prospective memory result	2.61	1	0	0.0	0.00	1.0e+00	MST1R
Current tobacco smoking	2.60	1	0	0.0	0.00	1.0e+00	SH3GL1P3
Exposure to tobacco smoke outside home	2.60	1	0	0.0	0.00	1.0e+00	MST1R
Schizophrenia (2018)	2.59	1	1	2.2	0.00	1.0e+00	FES
Frequency of tenseness / restlessness in last 2 weeks	2.59	1	0	0.0	0.00	1.0e+00	MST1R
Qualifications: NVQ or HND or HNC or equivalent	2.59	1	0	0.0	0.00	1.0e+00	MST1R
Crohns Disease (2017)	2.58	1	1	2.2	0.00	1.0e+00	MST1R
Ever smoked	2.58	3	0	0.0	0.00	1.0e+00	FES SH2B3 ZNF652
Qualifications: nursing, teaching	2.56	1	0	0.0	0.00	1.0e+00	MST1R
Mother's age at death	2.53	1	0	0.0	0.00	1.0e+00	PMS2P5
Worry (Nagel 2018)	2.51	1	1	2.2	0.00	1.0e+00	RPS6KL1
Medication: Co-codamol	2.51	1	0	0.0	0.00	1.0e+00	MST1R
Comparative height size at age 10	2.51	8	1	2.2	-0.31	4.5e-01	CGREF1 FAM108C1 FES PMS2P5 RPS6KL1 SH2B3 SH3GL1P3 SORT1
Had major operations	2.51	1	0	0.0	0.00	1.0e+00	ZNF652
Allergy or Eczema	2.49	3	1	2.2	0.00	1.0e+00	CISD2 SH2B3 ZNF652
Number of live births	2.49	2	0	0.0	0.00	1.0e+00	CISD2 MST1R
Type 2 Diabetes (T2D) (2012)	2.45	1	0	0.0	0.00	1.0e+00	CISD2
Seen doctor (GP) for nerves, anxiety, tension or depression	2.43	1	0	0.0	0.00	1.0e+00	RPS6KL1
Bipolar Disorder or Schizophrenia	2.38	1	1	2.2	0.00	1.0e+00	FES
Hand grip strength (left)	2.31	3	0	0.0	0.00	1.0e+00	MLLT10 RPS6KL1 SH3GL1P3
Osteoarthritis (self-reported)	2.31	1	0	0.0	0.00	1.0e+00	MST1R
Medication: Laxatives (e.g. Dulcolax, Senokot)	2.29	1	0	0.0	0.00	1.0e+00	CGREF1
Ever had bowel cancer screening	2.27	2	0	0.0	0.00	1.0e+00	MLLT10 MST1R
Rheumatoid Arthritis	2.21	1	0	0.0	0.00	1.0e+00	SH2B3
Worrier / anxious feelings	2.20	1	1	2.2	0.00	1.0e+00	RPS6KL1
Exposure to tobacco smoke at home	2.20	1	0	0.0	0.00	1.0e+00	MST1R
Qualifications: CSEs or equivalent	2.18	1	0	0.0	0.00	1.0e+00	MST1R
Pulse rate, automated reading	2.16	4	0	0.0	1.00	1.8e-04	CGREF1 MST1R PMS2P5 SORT1
Average weekly beer plus cider intake	2.15	1	1	2.2	0.00	1.0e+00	MST1R
Major Depression (MDD)	2.12	1	0	0.0	0.00	1.0e+00	RPS6KL1
Blood Red Count	2.12	3	1	2.2	0.00	1.0e+00	PMS2P5 SH2B3 TMEM133
Blood clot in the leg (DVT)	2.11	1	0	0.0	0.00	1.0e+00	SH2B3
Ever used hormone-replacement therapy (HRT)	2.10	1	0	0.0	0.00	1.0e+00	SH3GL1P3
Hayfever, allergic rhinitis or eczema	2.10	1	1	2.2	0.00	1.0e+00	ZNF652
Financial situation satisfaction	2.09	1	0	0.0	0.00	1.0e+00	MST1R
Neuroticism (2016)	2.06	1	0	0.0	0.00	1.0e+00	RPS6KL1
Mouth/teeth dental problems: Dentures	2.01	1	1	2.2	0.00	1.0e+00	MST1R
Age started oral contraceptive pill	2.00	2	0	0.0	0.00	1.0e+00	MST1R ZNF652
Hand grip strength (right)	1.95	2	0	0.0	0.00	1.0e+00	MLLT10 SH3GL1P3
Sensitivity / hurt feelings	1.93	1	0	0.0	0.00	1.0e+00	FES
Lung FVC	1.88	5	1	2.2	-0.71	1.8e-01	MLLT10 MST1R SH2B3 SH3GL1P3 TMEM133
Nervous feelings	1.84	1	1	2.2	0.00	1.0e+00	RPS6KL1
Forced expiratory volume in 1-second (FEV1)	1.79	3	0	0.0	0.00	1.0e+00	MST1R PPP2R2D TMEM133
Tense / 'highly strung'	1.79	1	0	0.0	0.00	1.0e+00	RPS6KL1
Standing height	1.78	8	6	13.3	-0.52	1.9e-01	CGREF1 PPP2R2D RPS6KL1 SH2B3 SH3GL1P3 SORT1 ZNF652 ZNF831
Height	1.75	9	8	17.8	-0.49	1.8e-01	CGREF1 FES PPP2R2D RPS6KL1 SH2B3 SH3GL1P3 SORT1 ZNF652 ZNF831
Fractured/broken bones in last 5 years	1.75	1	0	0.0	0.00	1.0e+00	SH3GL1P3
Relative age voice broke	1.66	1	0	0.0	0.00	1.0e+00	PMS2P5
Breast cancer (self-reported)	1.63	1	0	0.0	0.00	1.0e+00	MLLT10
Forced vital capacity (FVC)	1.62	4	0	0.0	-1.00	1.2e-03	MLLT10 MST1R PPP2R2D TMEM133
Suffer from 'nerves'	1.61	1	0	0.0	0.00	1.0e+00	RPS6KL1
Comparative body size at age 10	1.60	1	1	2.2	0.00	1.0e+00	ZNF652
Forced expiratory volume in 1-second (FEV1), Best measure	1.59	3	0	0.0	0.00	1.0e+00	MST1R PPP2R2D TMEM133
Heel bone mineral density (BMD) T-score, automated (left)	1.52	1	0	0.0	0.00	1.0e+00	MST1R
Forced vital capacity (FVC), Best measure	1.52	2	1	2.2	0.00	1.0e+00	MLLT10 MST1R
Irritability	1.50	1	0	0.0	0.00	1.0e+00	RPS6KL1
Myopia	1.42	1	0	0.0	0.00	1.0e+00	SH3GL1P3
Heel bone mineral density (BMD) T-score, automated (right)	1.39	1	0	0.0	0.00	1.0e+00	MST1R
Heel T-Score	1.37	6	1	2.2	0.16	7.6e-01	MST1R PMS2P5 RPS6KL1 SH3GL1P3 SORT1 TMEM133
Relative age of first facial hair	1.36	1	0	0.0	0.00	1.0e+00	PMS2P5
Sitting height	1.34	5	1	2.2	0.58	3.0e-01	CGREF1 MLLT10 PPP2R2D ZNF652 ZNF831
Mouth/teeth dental problems: Mouth ulcers	1.31	1	0	0.0	0.00	1.0e+00	SH2B3
Peak expiratory flow (PEF)	1.24	1	0	0.0	0.00	1.0e+00	MLLT10
Hair Pigment	0.64	5	3	6.7	0.14	8.2e-01	CGREF1 FES SH2B3 SH3GL1P3 ZNF831
Tanning	0.39	2	0	0.0	0.00	1.0e+00	RPS6KL1 SH2B3

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Cerebellum	5	0.252	2.1
GTEx	Artery Aorta	6	0.202	2.0
GTEx	Skin Not Sun Exposed Suprapubic	7	0.285	2.0
GTEx	Small Intestine Terminal Ileum	2	0.434	2.0
GTEx	Adipose Subcutaneous	3	0.086	1.9
GTEx	Adipose Visceral Omentum	2	0.098	1.9
GTEx	Artery Tibial	7	0.186	1.9
GTEx	Brain Cerebellar Hemisphere	3	0.201	1.9
GTEx	Brain Cortex	3	0.290	1.9
GTEx	Brain Frontal Cortex BA9	2	0.216	1.9
GTEx	Brain Hippocampus	0	0.000	1.9
GTEx	Breast Mammary Tissue	3	0.152	1.9
GTEx	Cells Transformed fibroblasts	8	0.191	1.9
GTEx	Colon Sigmoid	3	0.205	1.9
GTEx	Esophagus Gastroesophageal Junction	3	0.208	1.9
GTEx	Esophagus Mucosa	6	0.181	1.9
GTEx	Heart Atrial Appendage	2	0.127	1.9
GTEx	Lung	5	0.174	1.9
GTEx	Muscle Skeletal	4	0.138	1.9
GTEx	Pancreas	2	0.123	1.9
GTEx	Prostate	1	0.120	1.9
GTEx	Skin Sun Exposed Lower leg	8	0.220	1.9
GTEx	Testis	3	0.095	1.9
GTEx	Whole Blood	2	0.100	1.9
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.9
GTEx	Adrenal Gland	3	0.206	1.8
GTEx	Artery Coronary	2	0.169	1.8
GTEx	Brain Caudate basal ganglia	2	0.217	1.8
GTEx	Breast Mammary Tissue (Male)	1	0.084	1.8
GTEx	Breast Mammary Tissue (Female)	2	0.122	1.8
GTEx	Cells EBV-transformed lymphocytes	1	0.070	1.8
GTEx	Colon Transverse	3	0.145	1.8
GTEx	Esophagus Muscularis	4	0.124	1.8
GTEx	Heart Left Ventricle	1	0.065	1.8
GTEx	Liver	1	0.139	1.8
GTEx	Nerve Tibial	6	0.139	1.8
GTEx	Ovary	1	0.110	1.8
GTEx	Pituitary	1	0.090	1.8
GTEx	Spleen	3	0.213	1.8
GTEx	Stomach	2	0.138	1.8
GTEx	Thyroid	5	0.125	1.8
GTEx	Vagina	1	0.157	1.8
METSIM	Adipose	4	0.087	1.8
NTR	Blood	3	0.125	1.8
ROSMAP	Brain Pre-frontal Cortex	10	0.228	1.8
CommonMind	Brain Pre-frontal Cortex	8	0.149	1.8
The Cancer Genome Atlas	Breast Invasive Carcinoma	6	0.136	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	4	0.147	1.8
The Cancer Genome Atlas	Lung Adenocarcinoma	7	0.238	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	3	0.181	1.8
The Cancer Genome Atlas	Stomach Adenocarcinoma	3	0.178	1.8
The Cancer Genome Atlas	Thyroid Carcinoma	4	0.078	1.8
GTEx	Brain Nucleus accumbens basal ganglia	1	0.116	1.7
GTEx	Brain Putamen basal ganglia	1	0.160	1.7
GTEx	Uterus	1	0.176	1.7
YFS	Blood	3	0.065	1.7
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.7
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	1	0.091	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	2	0.097	1.7
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.146	1.7
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.7
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	5	0.122	1.7
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.7
The Cancer Genome Atlas	Brain Lower Grade Glioma	5	0.116	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	2	0.080	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	1	0.063	1.7
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	1	0.075	1.7
The Cancer Genome Atlas	Prostate Adenocarcinoma	5	0.108	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	1	0.094	1.7
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.7
GTEx	Brain Hypothalamus	0	0.000	1.6
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.5